CALQUENCE Market Summary

Key Factors Driving CALQUENCE Growth

1. Expansion into first-line CLL/SLL with a fixed-duration regimen is a major growth driver:

In February 2026, the FDA approved CALQUENCE + venetoclax as the first all-oral, fixed-duration BTK-inhibitor regimen for previously untreated CLL/SLL. In the Phase III AMPLIFY trial, 77% of patients receiving CALQUENCE + venetoclax were progression-free at 3 years versus 67% with chemoimmunotherapy, with a 35% reduction in the risk of progression or death (HR 0.65; p=0.0038). The trial enrolled patients across 27 countries, and AstraZeneca estimates that approximately 18,500 patients were treated in the first-line CLL setting in the U.S. in 2024. The new fixed-duration option can therefore expand CALQUENCE utilization among newly diagnosed patients.

2. Strong long-term efficacy in CLL supports continued use across treatment settings:

Six-year ELEVATE-TN results showed that CALQUENCE-based therapy maintained substantial progression-free survival benefits in previously untreated CLL. At 72 months, estimated PFS was 78.0% with CALQUENCE + obinutuzumab and 61.5% with CALQUENCE monotherapy, compared with 17.2% for chlorambucil + obinutuzumab. CALQUENCE + obinutuzumab also significantly improved overall survival versus the chemoimmunotherapy comparator. These durable outcomes support CALQUENCE's established position in a chronic disease requiring long-term treatment.

3. Demonstrated efficacy in relapsed/refractory CLL provides a durable commercial base:

In the final approximately four-year ASCEND analysis, CALQUENCE significantly prolonged PFS versus investigator's choice of idelalisib + rituximab or bendamustine + rituximab. Median PFS was not reached with CALQUENCE versus 16.8 months with the comparator, while 42-month PFS was 62% versus 19%. This evidence supports continued use in previously treated CLL and helps maintain CALQUENCE's existing revenue base as treatment paradigms evolve.

4. First-line mantle cell lymphoma (MCL) expansion opens an additional patient population:

In January 2025, the FDA approved CALQUENCE + bendamustine/rituximab for previously untreated MCL patients who are ineligible for autologous stem-cell transplantation. The ECHO Phase III trial demonstrated a 27% reduction in the risk of disease progression or death (HR 0.73; p=0.016), with median PFS of 66.4 months versus 49.6 months with chemoimmunotherapy—a difference of approximately 17 months. The European Commission subsequently approved the same first-line MCL combination in May 2025. AstraZeneca estimates more than 21,000 MCL patients across the U.S., UK, France, Germany, Spain, Italy, Japan and China.

CALQUENCE Recent Developments

In February 2026, AstraZeneca’s CALQUENCE (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).

“CALQUENCE Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of CALQUENCE for approved indication like Chronic lymphocytic leukaemia and Mantle-cell lymphoma; as well as potential indication like Diffuse large B cell lymphoma, B-cell lymphoma, Bladder cancer, Head and neck cancer, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, and Ovarian cancer in the 7MM. A detailed picture of CALQUENCE’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the CALQUENCE for approved and potential indications. The CALQUENCE market report provides insights about CALQUENCE’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current CALQUENCE performance, future market assessments inclusive of the CALQUENCE market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of CALQUENCE sales forecasts, along with factors driving its market.

CALQUENCE Drug Summary

CALQUENCE is a highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor developed by AstraZeneca for the treatment of certain B-cell malignancies. It works by irreversibly binding to BTK, a key enzyme in the B-cell receptor signaling pathway, thereby inhibiting downstream signaling involved in B-cell proliferation, survival, activation, and migration. By disrupting these pathways, acalabrutinib suppresses the growth and survival of malignant B cells. CALQUENCE is available as an oral capsule and tablet formulation, allowing convenient administration compared with intravenous cancer therapies. The report provides CALQUENCE’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the CALQUENCE Market Report

The report provides insights into:

• A comprehensive product overview including the CALQUENCE MoA, description, dosage and administration, research and development activities in approved indications like Chronic lymphocytic leukaemia and Mantle-cell lymphoma; as well as potential indication like Diffuse large B cell lymphoma, B-cell lymphoma, Bladder cancer, Head and neck cancer, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, and Ovarian cancer.
• Elaborated details on CALQUENCE regulatory milestones and other development activities have been provided in CALQUENCE market report.
• The report also highlights CALQUENCE‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The CALQUENCE market report also covers the patents information, generic entry and impact on cost cut.
• The CALQUENCE market report contains current and forecasted CALQUENCE sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The CALQUENCE market report also features the SWOT analysis with analyst views for CALQUENCE in approved and potential indications.

Methodology

The CALQUENCE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CALQUENCE Analytical Perspective by DelveInsight

• In-depth CALQUENCE Market Assessment

This CALQUENCE sales market forecast report provides a detailed market assessment of CALQUENCE for approved indication like Chronic lymphocytic leukaemia and Mantle-cell lymphoma; as well as potential indication like Diffuse large B cell lymphoma, B-cell lymphoma, Bladder cancer, Head and neck cancer, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, and Ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted CALQUENCE sales data uptil 2034.

• CALQUENCE Clinical Assessment

The CALQUENCE market report provides the clinical trials information of CALQUENCE for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

CALQUENCE Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

CALQUENCE Market Potential & Revenue Forecast

• Projected market size for the CALQUENCE and its key indications
• Estimated CALQUENCE sales potential (CALQUENCE peak sales forecasts)
• CALQUENCE Pricing strategies and reimbursement landscape

CALQUENCE Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• CALQUENCE Market positioning compared to existing treatments
• CALQUENCE Strengths & weaknesses relative to competitors

CALQUENCE Regulatory & Commercial Milestones

• CALQUENCE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

CALQUENCE Clinical Differentiation

• CALQUENCE Efficacy & safety advantages over existing drugs
• CALQUENCE Unique selling points

CALQUENCE Market Report Highlights

• In the coming years, the CALQUENCE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The CALQUENCE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CALQUENCE’s dominance.
• Other emerging products for Chronic lymphocytic leukaemia and Mantle-cell lymphoma; as well as potential indication like Diffuse large B cell lymphoma, B-cell lymphoma, Bladder cancer, Head and neck cancer, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, and Ovarian cancer are expected to give tough market competition to CALQUENCE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CALQUENCE in approved and potential indications.
• Analyse CALQUENCE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted CALQUENCE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of CALQUENCE in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of CALQUENCE? How strong is CALQUENCE’s clinical and commercial performance?
• What is CALQUENCE’s clinical trial status in each individual indications such as Chronic lymphocytic leukaemia and Mantle-cell lymphoma; as well as potential indication like Diffuse large B cell lymphoma, B-cell lymphoma, Bladder cancer, Head and neck cancer, Non-Hodgkin’s lymphoma, Non-small cell lung cancer, and Ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CALQUENCE Manufacturers?
• What are the key designations that have been granted to CALQUENCE for approved and potential indications? How are they going to impact CALQUENCE’s penetration in various geographies?
• What is the current and forecasted CALQUENCE market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of CALQUENCE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to CALQUENCE for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is CALQUENCE? What is the duration of therapy and what are the geographical variations in cost per patient?